Focalpoint invests in early stage startups driving Human 3: the era of exponential human flourishing. 

‍

While modern medicine (Human 2) benefited society in incalculable ways, it ultimately fell short of its promise because the available tools forced it to operate at an incremental pace with long feedback loops.

‍

Today, exponential technologies like AI - which can parse through terabytes of scientific literature and data in seconds - and brain-computer-interfaces, biosensors and CRISPR - which enable real-time, read-write access to our biology - promise to rapidly accelerate the scientific method flywheel and lead to an exponential explosion in health, wellness and performance. 

‍

Human 3 will elevate every area of health and wellbeing, but will have the biggest impact in areas where modern medicine has made the least progress: the mental health crisis, neurodegeneration, chronic disease and aging. These are the “focal points” of our investment strategy. 

‍

Human 3 is not a “sector” - our companies combine life sciences, AI, hardware, software, deep tech & health tech in novel ways that often defy conventional categorization. Human 3 is a philosophy of vitality. It is a knowing that the “user experience” of the human body and mind is long overdue for an upgrade. It is the willingness to build and invest in that future. This is Human 3.   

‍

This movement marks the third great epoch of human health: 

• Human 1 was defined by medieval practices like bloodletting and humorism - medicine before evidence. 

• Human 2 was the era of “modern” medicine, which began in the 1850s when Louis Pasteur popularized the germ theory of disease and the scientific method became the gold standard. Human 2 was constrained by both incremental tools and artificial boundaries between disciplines.

• Human 3 builds on Human 2’s legacy of scientific rigour, but is accelerated by exponential technologies, transdisciplinary collaborations, and driven by a belief that we can do so much more to not just heal the sick, but to prevent illness in the first place and elevate the already healthy. 

We’ve already backed some of Human 3’s genre-defining companies like Kerna Labs, Motif Neurotech, Xylo, NeuroBionics, and Superpower at their earliest stages. We’ve helped them secure pharma partnerships, hire their best talent and raise millions in follow-on financing - and we're just getting started.

‍

If you're a founder building in Human 3 we'd love to speak with you. Please reach out at hello at our domain

‍

Looking to work in Human 3? View our portfolio companies' open roles here.

‍

Our portfolio companies include: 

‍